List view / Grid view
14 October 2015 | By Victoria White
The three-year collaboration will focus on mechanistic approaches for the identification of genes or signalling pathways that modify neurodegenerative disease processes affecting neuronal health...
12 October 2015 | By Victoria White
The Dementia Consortium is a £3.5m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology, Eisai, Lilly and now Astex...
9 October 2015 | By Victoria White
Researchers reported that treatment with IFNβ-gene therapy successfully prevented neuronal death and disease effects in an experimental model of the disease...
5 October 2015 | By Victoria White
Rats given RGFP966 were more attuned to what they were hearing and were able to retain and remember more information...
16 September 2015 | By Victoria White
A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) will join forces with MRC Technology to take on the project...
28 July 2015 | By Victoria White
UMG and MRC Technology are to collaborate to develop a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x...
21 July 2015 | By Victoria White
Examining post-mortem tissue from the brains of people with Alzheimer's disease, researchers identified iron-containing microglia in the hippocampus...
20 July 2015 | By Victoria White
Certain patients with type 2 diabetes may have specific genetic risk factors that put them at higher risk for developing Alzheimer’s disease...
13 July 2015 | By Victoria White
Probiodrug is to provide funding to further investigate the potential of pGlu-Abeta antibodies for passive vaccination against Alzheimer's disease...
24 June 2015 | By Victoria White
Scientists have identified a single blood protein that may indicate the development a disorder associated with an increased risk of Alzheimer's disease...
22 June 2015 | By Victoria White
The Dementia Consortium is funding a new project to target the immune system in the hunt for new treatments for Alzheimer's disease...
11 June 2015 | By Victoria White
Researchers have identified a naturally occurring variant of the human prion protein that produces resistance to prion diseases such as CJD...
Dementia is a global crisis with 76 million people worldwide expected to be living with the condition by 2030. Current symptomatic treatments provide modest improvements in cognition but disease-modifying therapies for diseases like Alzheimer’s – the most common cause of dementia – do not yet exist.
9 June 2015 | By Victoria White
A new study has revealed that calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, may also protect against Alzheimer’s disease...
26 March 2015 | By Victoria White
New treatments, diagnostics and medical technologies are set to benefit from an investment of £32 million through the Biomedical Catalyst...
